Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Germline Genetic Testing in Unselected Squamous and Non‐Squamous Head and Neck Cancers
Brake, Daniela A. , Golafshar, Michael A. , Young, Sarah , Klint, Margaret, Barrus, Kathleen , Samadder, N. Jewel , Hinni, Michael L., Idler, Beau M. , Kunze, Katie L. , Chang, Brent A , Golafshar, Michael , Leach, Brandie , Esplin, Edward D. , Nussbaum, Robert L. , Chang, Brent A.

Mayo Clinic

The Laryngoscope | May 3, 2023 | Volume: 133 | Issue: 12 | Pages: 3378-3388

10.1002/lary.30720 | PMID 37132629 Get It

ObjectiveThis study describes the prevalence of pathogenic germline variants (PGVs) in head and neck cancer patients, the incremental yield compared to a guideline‐based approach to genetic evaluation, and the uptake of family variant testing.Study DesignProspective cohort study.SettingThree tertiary academic medical centers.MethodsGermline sequencing using an 84‐gene screening platform among unselected head and neck cancer patients who received care at Mayo Clinic Cancer Centers between April 2018 and March 2020.ResultsAmongst 200 patients, the median age was 62.0 years (Q1, Q3: 55, 71), 23.0% were female, 89.0% white/non‐Hispanic, 5.0% Hispanic/Latinx, 6% of another race, and 42.0% had prognostic stage IV disease. The most common subsites were the oropharyngeal (45.0%) and salivary glands (12.0%). The most common histology was squamous cell carcinoma (74.5%). Twenty‐one patients (10.5%) had a total of 22 PGVs; 20 of the 21 patients (95.2%) did not meet criteria for testing by current guidelines. Regarding penetrance of the 22 PGVs, 11 were high or moderate (most commonPMS2orHOXB13), and 11 were low or recessive (most commonMUTYH,WNR, orRECQL4). One patient had a change in care based on an identified PGV. Family variant testing was completed at a rate of 4.8%.ConclusionsUniversal gene panel testing identified a PGV in 10.5% of head and neck cancer patients; almost all would have been missed by current guideline‐based testing. One of 21 patients had a treatment change due to their PGV, indicating that head and neck cancer treatment decisions are not yet widely informed by germline alterations.Level of Evidence3Laryngoscope, 133:3378–3388, 2023
A Systematic Review of Methods Used to Determine the Work of Breathing during Exercise
Isautier, Jennifer , Hubbard, Colin D. , Morris, Sarah J. , Smith, Joshua R. , Duke, Joseph W. , Smith, Joshua R , Cross, Troy J. , Kelley, Eli F. , Hubbard, Colin D.

Mayo Clinic

Medicine & Science in Sports & Exercise | May 1, 2023 | Volume: 55 | Issue: 9 | Pages: 1672-1682

10.1249/mss.0000000000003187 | PMID 37126027 Get It

ABSTRACT Introduction Measurement of the work of breathing (Wb) during exercise provides useful insights into the energetics and mechanics of the respiratory muscles across a wide range of minute ventilations. The methods and analytical procedures used to calculate the Wb during exercise have yet to be critically appraised in the literature. Purpose The aim of this systematic review was to evaluate the quality of methods used to measure the Wb during exercise in the available literature. Methods We conducted an extensive search of three databases for studies that measured the Wb during exercise in adult humans. Data were extracted on participant characteristics, flow/volume and pressure devices, esophageal pressure (P oes ) catheters, and methods of Wb analysis. Results A total of 120 articles were included. Flow/volume sensors used were primarily pneumotachographs ( n = 85, 70.8%), whereas the most common pressure transducer was of the variable reluctance type ( n = 63, 52.5%). Esophageal pressure was frequently obtained via balloon-tipped catheters ( n = 114, 95.0%). Few studies mentioned calibration, frequency responses, and dynamic compensation of their measurement devices. The most popular method of measuring the Wb was pressure–volume integration ( n = 51, 42.5%), followed by the modified Campbell ( n = 28, 23.3%) and Dean & Visscher diagrams ( n = 26, 21.7%). Over one-third of studies did not report the methods used to process their pressure–volume data, and the majority (60.8%) of studies used the incorrect Wb units and/or failed to discuss the limitations of their Wb measurements. Conclusions The findings of this systematic review highlight the need for the development of a standardized approach for measuring Wb, which is informative, practical, and accessible for future researchers.
Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?
Desai, Aakash , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Clinical Cancer Research | May 1, 2023 | Volume: 29 | Issue: 13 | Pages: 2339-2341

10.1158/1078-0432.ccr-23-0746 | PMID 37125861 Get It

Summary Genome driven precision oncology has transformed the landscape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that offered free tumor genomic testing with a focus on rare cancers. See related article by Doe-Tetteh et al., p. 2445
Angiotensin II for Treatment of Calcium Channel Blocker Overdose
Felzer, Jamie , Chalmers, Sarah , Hoskote, Sumedh S.

Mayo Clinic

C48. CASE REPORTS: TOXICOLOGY AND OTHER INVOLVING MEDICATIONS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5207-A5207

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5207 Get It

Deep Residual Convolutional Network Predicts Future Severe Exacerbations of COPD in SPIROMICS
Awan, Hira A. , Chaudhary, Muhammad F. A. , Bhatt, S.P. , Cooper, C.B., Criner, G.J., Hansel, N.N., Krishnan, J.A., Ortega, Victor E. , Paine, Robert , Schroeder, Joyce , Gerard, Sarah E. , Comellas, Alejandro P. , Hoffman, Eric A. , Barjaktarević, Igor , Bhatt, Surya P. , Cooper, C.B. , Criner, G.J., Reinhardt, Joseph M.

Mayo Clinic

B41. RISK FACTORS AND OUTCOMES FOR COPD EXACERBATIONS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A3318-A3318

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3318 Get It

Survey and Evaluation of Hypertension Machine Learning Research
Toit, Clea du , Tran, Tran , Deo, Neha , Aryal, Sachin , Lip, Stefanie , Sykes, Robert , Manandhar, Ishan , Sionakidis, Aristeidis , Pattnaik, Harsha , Alsanosi, Safaa , Kassi, Maria, Lê, Ngọc Minh, Rostron, Maggie , Nichol, Sarah , Mehta, Dhruven , Tummala, Ramakumar , Reddy, Sandeep , Visweswaran, Shyam , Joe, Bina , Le, Nhu Ngoc , du Toit, Clea , Tran, Tran Quoc Bao , Pattnaik, Harsha , Alsanosi, Safaa , Rostron, Maggie , Nichol, Sarah , Aman, Alisha , Nawaz, Faisal A , Mehta, Dhruven , Tummala, Ramakumar , McCallum, Linsay , Reddy, Sandeep , Visweswaran, Shyam , Kashyap, Rahul , Joe, Bina , Padmanabhan, Sandosh , Deo, Neha N , Stevenson, Leah, Nawaz, Faisal A. , Kashyap, Rahul , Padmanabhan, Sandosh

Mayo Clinic

Journal of the American Heart Association | April 29, 2023 | Volume: 12 | Issue: 9 | Pages: No page available

10.1161/jaha.122.027896 | PMID 37119074 Get It

Background Machine learning (ML) is pervasive in all fields of research, from automating tasks to complex decision‐making. However, applications in different specialities are variable and generally limited. Like other conditions, the number of studies employing ML in hypertension research is growing rapidly. In this study, we aimed to survey hypertension research using ML, evaluate the reporting quality, and identify barriers to ML's potential to transform hypertension care. Methods and Results The Harmonious Understanding of Machine Learning Analytics Network survey questionnaire was applied to 63 hypertension‐related ML research articles published between January 2019 and September 2021. The most common research topics were blood pressure prediction (38%), hypertension (22%), cardiovascular outcomes (6%), blood pressure variability (5%), treatment response (5%), and real‐time blood pressure estimation (5%). The reporting quality of the articles was variable. Only 46% of articles described the study population or derivation cohort. Most articles (81%) reported at least 1 performance measure, but only 40% presented any measures of calibration. Compliance with ethics, patient privacy, and data security regulations were mentioned in 30 (48%) of the articles. Only 14% used geographically or temporally distinct validation data sets. Algorithmic bias was not addressed in any of the articles, with only 6 of them acknowledging risk of bias. Conclusions Recent ML research on hypertension is limited to exploratory research and has significant shortcomings in reporting quality, model validation, and algorithmic bias. Our analysis identifies areas for improvement that will help pave the way for the realization of the potential of ML in hypertension and facilitate its adoption.
Peripheral Nerve Pathology in Antibody Positive Paraneoplastic Neurological Syndromes (P11-8.005)
Granger, Andre , Rajnauth, Tina , Mills, John R. , Mauermann, Michelle L. , Berini, Sarah E. , Dyck, Peter James , Mauermann, Michelle L , Dubey, Divyanshu , Klein, Christopher J.

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000203395 Get It

Frontal cognitive-behavioural deficits in patients with anti-leucine-rich glioma-inactivated protein 1 antibody encephalitis (S22.004)
Lee, Sydney , Day, Gregory S. , Hébert, Julien , LaPointe, S. , Wennberg, Richard , Muccilli, Alexandra, Tang‐Wai, David F. , Day, Gregory S , Climans, Seth , Lapointe, Sarah, Ramos, Ronald , Steriade, Claude

Mayo Clinic

Neurology | April 28, 2023 | Volume: 100 | Issue: 17_supplement_2 | Pages: No page available

10.1212/wnl.0000000000202815 Get It

Risk Factors for Stiffness Requiring Intervention After Ream-and-Run Arthroplasty
Schiffman, Corey J. , Jurgensmeier, Kevin , Yao, Jie , Wu, John , Whitson, Anastasia J. , Jackins, Sarah E. , Matsen, Frederick A. , Hsu, Jason E. , Yao, Jie J , Wu, John C , Jurgensmeier, Kevin

Mayo Clinic

JBJS Open Access | April 27, 2023 | Volume: 8 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.22.00104 | PMID 37123506 Get It

Background: Ream-and-run arthroplasty can improve pain and function in patients with glenohumeral arthritis while avoiding the complications and activity restrictions associated with a prosthetic glenoid component. However, stiffness is a known complication after ream-and-run arthroplasty and can lead to repeat procedures such as a manipulation under anesthesia (MUA) or open surgical revision. The objective of this study was to determine risk factors associated with repeat procedures indicated for postoperative stiffness after ream-and-run arthroplasty. Methods: We conducted a retrospective review of our shoulder arthroplasty database to identify patients who underwent ream-and-run arthroplasty and determined which patients underwent subsequent repeat procedures (MUA and/or open revision) indicated for postoperative stiffness. The minimum follow-up was 2 years. We collected baseline demographic information and preoperative and 2-year patient-reported outcome scores and analyzed preoperative radiographs. Univariate and multivariate analyses determined the factors significantly associated with repeat procedures to treat postoperative stiffness. Results: There were 340 patients who underwent ream-and-run arthroplasty. The mean Simple Shoulder Test (SST) scores for all patients improved from 5.0 ± 2.4 preoperatively to 10.2 ± 2.6 postoperatively (p < 0.001). Twenty-six patients (7.6%) underwent open revision for stiffness. An additional 35 patients (10.3%) underwent MUA. Univariate analysis found younger age (p = 0.001), female sex (p = 0.034), lower American Society of Anesthesiologists (ASA) class (p = 0.045), posterior decentering on preoperative radiographs (p = 0.010), and less passive forward elevation at the time of discharge after ream-and-run arthroplasty (p < 0.001) to be significant risk factors for repeat procedures. Multivariate analysis found younger age (p = 0.040), ASA class 1 compared with class 3 (p = 0.020), and less passive forward elevation at discharge (p < 0.001) to be independent risk factors for repeat procedures. Of the patients who underwent open revision for stiffness, 69.2% had multiple positive cultures for Cutibacterium. Conclusions: Younger age, ASA class 1 compared with class 3, and less passive forward elevation in the immediate postoperative period were independent risk factors for repeat procedures to treat postoperative stiffness after ream-and-run arthroplasty. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
C-terminal TMEM106B fragments in human brain correlate with disease-associated TMEM106B haplotypes
Vicente, Cristina T. , Perneel, Jolien , Wynants, Sarah , Heeman, Bavo , Broeck, Marleen Van den , Baker, Matt , Cheung, Simon, Faura, Júlia , Mackenzie, Ian R. , Rademakers, Rosa

Mayo Clinic

Brain | April 26, 2023 | Volume: 146 | Issue: 10 | Pages: 4055-4064

10.1093/brain/awad133 | PMID 37100087 Get It

Abstract Transmembrane protein 106B (TMEM106B) is a tightly regulated glycoprotein predominantly localized to endosomes and lysosomes. Genetic studies have implicated TMEM106B haplotypes in the development of multiple neurodegenerative diseases with the strongest effect in frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), especially in progranulin (GRN) mutation carriers. Recently, cryo-electron microscopy studies showed that a C-terminal fragment (CTF) of TMEM106B (amino acid residues 120–254) forms amyloid fibrils in the brain of patients with FTLD-TDP, but also in brains with other neurodegenerative conditions and normal ageing brain. The functional implication of these fibrils and their relationship to the disease-associated TMEM106B haplotype remain unknown. We performed immunoblotting using a newly developed antibody to detect TMEM106B CTFs in the sarkosyl-insoluble fraction of post-mortem human brain tissue from patients with different proteinopathies (n = 64) as well as neuropathologically normal individuals (n = 10) and correlated the results with age and TMEM106B haplotype. We further compared the immunoblot results with immunohistochemical analyses performed in the same study population. Immunoblot analysis showed the expected ∼30 kDa band in the sarkosyl-insoluble fraction of frontal cortex tissue in at least some individuals with each of the conditions evaluated. Most patients with GRN mutations showed an intense band representing TMEM106B CTF, whereas in most neurologically normal individuals it was absent or much weaker. In the overall cohort, the presence of TMEM106B CTFs correlated strongly with both age (rs = 0.539, P &lt; 0.001) and the presence of the TMEM106B risk haplotype (rs = 0.469, P &lt; 0.001). Although there was a strong overall correlation between the results of immunoblot and immunohistochemistry (rs = 0.662, P &lt; 0.001), 27 cases (37%) were found to have higher amounts of TMEM106B CTFs detected by immunohistochemistry, including most of the older individuals who were neuropathologically normal and individuals who carried two protective TMEM106B haplotypes. Our findings suggest that the formation of sarkosyl-insoluble TMEM106B CTFs is an age-related feature which is modified by TMEM106B haplotype, potentially underlying its disease-modifying effect. The discrepancies between immunoblot and immunohistochemistry in detecting TMEM106B pathology suggests the existence of multiple species of TMEM106B CTFs with possible biological relevance and disease implications.